^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Ovarian Serous Adenocarcinoma |
| Drug: | prexasertib (ACR-368) (Chk2 inhibitor, Chk1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Excerpt:
...Participants enrolling in the sporadic high grade serous epithelial or high grade endometrioid ovarian cancer group, Cohort 2, must have a negative family history of hereditary breast ovarian cancer (HBOC) syndrome, or negative gBRCA1/2m mutation test....
Trial ID:
Source:
Title:
BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer
Published date:
06/21/2023
Excerpt:
The aim of this study was to investigate the clinical activity of CHK1i prexasertib in PARPi-resistant BRCA-mutant HGSC and to identify potential biomarkers for CHK1i response….IC50 values for prexasertib monotherapy ranged from 1.2 to 30.6 nM in PARPi-sensitive and -resistant BRCA-mutant HGSC cells...
DOI:
10.1126/scitranslmed.add7872
